Citation Impact
Citing Papers
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Complement drives Th17 cell differentiation and triggers autoimmune arthritis
2010 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia
1998
The chemistry and biology of mucin-type O-linked glycosylation
2005 StandoutNobel
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Preoperative chemotherapy for non-small cell lung cancer
2001
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
2000
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma
1989
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma
2000
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
2022 StandoutNobel
Advances in the Treatment of Malignant Pleural Mesothelioma
1999
Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei Krebspatienten
1997
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
1991
The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia
1997
Carboplatin: current status and future prospects
1988
Platelets and the immune continuum
2011 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Chemotherapy for Malignant Pleural Mesothelioma
2003
The evaluation and management of platelet refractoriness and alloimmunization
2000
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Chemistry in living systems
2005 StandoutNobel
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
1991
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
2000
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
1999
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells
2006
Disseminated Intravascular Coagulation
1999 Standout
A Review of Chemotherapy Trials for Malignant Mesothelioma
1998
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Small-cell lung cancer
2005
Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer
2002
Designing dendrimers for biological applications
2005 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
2004
Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer
2008
Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy
2004
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
MUC1, The Renaissance Molecule
2001
Advances in Malignant Mesothelioma
2005 Standout
Anemia of Chronic Disease
2005 Standout
Small-cell lung cancer
2011
Cancer of the Ovary
2004 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Synthesis of Novel gluco‐ and galacto‐Functionalized Platinum Complexes
2009
Control of the Molecular Orientation of Membrane-Anchored Biomimetic Glycopolymers
2009 StandoutNobel
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
1999
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
1992
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
2003
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
1996 Standout
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
The reversible binding of vinblastine to platelets: implications for therapy
1981
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
1999
Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection
2001
Chemotherapy for advanced gastric cancer
2017 Standout
A diagnostic test for heparin-induced thrombocytopenia
1986 Standout
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
1992
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Basic principles in the use of adjuvant therapy.
1990
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2004 Standout
Glycosylation and the Immune System
2001 Science
Pleural mesothelioma: combined modality treatments
2002
A prospective study of the usefulness of the measurement of platelet- associated IgG for the diagnosis of idiopathic thrombocytopenic purpura
1982
A mini-review on platelet refractoriness.
2005
Immune-mediated thrombocytopenia of malaria.
1983
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
1999
Autoimmune thrombocytopenic purpura
1980
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Chemical Glycoproteomics
2016 StandoutNobel
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
1981 Standout
Works of J. Bishop being referenced
The definition of refractoriness to platelet transfusions
1992
The immunogenicity of MUC1 peptides and fusion protein
1995
Factors influencing 20‐hour increments after platelet transfusion
1991
Phase II trial of carboplatin in the management of malignant mesothelioma.
1990
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
1996
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
1987
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
1998
A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation.
1988
Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma
1994
The direct assay for platelet-associated IgG (PAIgG): lack of association between antibody level and platelet size
1979
Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma
1987
The influence of pretreatment optimism on outcome in patients given radical radiotherapy for non-small cell lung cancer
2000